Sutent

sunitinib

  • Email
  • Help

About

This is a summary of the European public assessment report (EPAR) for Sutent. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Sutent.

What is Sutent?

Sutent is a medicine that contains the active substance sunitinib. It is available as capsules (12.5 mg, 25 mg, 37.5 mg and 50 mg).

What is Sutent used for?

Sutent is used to treat adults with the following types of cancer:

  • gastrointestinal stromal tumour (GIST), a type of cancer of the stomach and bowel where there is uncontrolled growth of cells in the supporting tissues of these organs. Sutent is used in patients with GISTs that cannot be removed with surgery or have spread to other parts of the body. It is used after treatment with imatinib (another cancer medicine) has failed;
  • metastatic renal cell carcinoma, a type of kidney cancer, that has spread to other parts of the body;
  • pancreatic neuroendocrine tumours (tumours of the hormone-producing cells in the pancreas) that have spread or cannot be removed with surgery. Sutent is used if the disease is getting worse and the tumour cells are well-differentiated (similar to normal cells in the pancreas).

The medicine can only be obtained with a prescription.

How is Sutent used?

Treatment with Sutent should be started by doctors who have experience in administering cancer medicines.

For GIST and metastatic renal cell carcinoma, Sutent is given in six-week cycles, at a dose of 50 mg once a day for four weeks, followed by a two-week ‘rest period’. The dose can be adjusted according to the patient’s response to the treatment, but should be kept within the range of 25 to 75 mg.

For pancreatic neuroendocrine tumours, Sutent is given at a dose of 37.5 mg once a day without a rest period. This dose may also be adjusted.

How does Sutent work?

The active substance in Sutent, sunitinib, is a protein kinase inhibitor. This means that it blocks some specific enzymes known as protein kinases. These enzymes can be found in some receptors at the surface of cancer cells, where they are involved in the growth and spread of cancer cells and in the blood vessels that supply the tumours, where they are involved in the development of new blood vessels. By blocking these enzymes, Sutent can reduce the growth and spread of the cancer and cut off the blood supply that keeps cancer cells growing.

How has Sutent been studied?

Sutent was compared with placebo (a dummy treatment) in 312 patients with GIST whose previous treatment with imatinib had failed and in 171 patients with worsening pancreatic neuroendocrine tumours that could not be removed with surgery. Sutent was also compared with another cancer medicine, interferon alfa, in 750 patients with metastatic renal cell carcinoma whose cancer had not been treated before.

The main measure of effectiveness in all of the studies was how long the patients lived without their tumours getting worse.

What benefit has Sutent shown during the studies?

Sutent was more effective than placebo in treating GIST and pancreatic neuroendocrine tumours. Patients with GIST taking Sutent lived for an average of 26.6 weeks without the disease getting worse, compared with 6.4 weeks in the patients taking placebo. For pancreatic neuroendocrine tumours the figures were 11.4 months in the Sutent group and 5.5 months in the placebo group.

In metastatic renal cell carcinoma, patients taking Sutent lived for an average of 47.3 weeks without their disease worsening, compared with 22.0 weeks in the patients receiving interferon alfa.

What is the risk associated with Sutent?

The most common side effects with Sutent (seen in more than 1 in 10 patients) include fatigue (tiredness), gastrointestinal disorders (such as diarrhoea, feeling sick, inflammation of the lining of the mouth, indigestion and vomiting), respiratory (such as shortness of breath and cough) and skin disorders (such as skin discoloration, dryness of the skin and rash), hair color changes, dysgeusia (taste disturbances), epistaxis (nosebleeds), loss of appetite, hypertension (high blood pressure), palmar-plantar erythrodysaesthesia syndrome (rash and numbness on the palms and soles), hypothyroidism (an underactive thyroid gland), insomnia (difficulty falling and staying asleep), dizziness, headache, arthralgia (joint pain), neutropenia (low levels of neutrophils, a type of white blood cell), thrombocytopenia (low blood platelet counts), anaemia (low red blood cell counts), and leucopenia (low white blood cell counts).

The most serious side effects reported with Sutent include heart and kidney failure, pulmonary embolism (clot in a blood vessel supplying the lungs), gastrointestinal perforation (holes in the wall of the gut), and internal haemorrhages (bleeding).

For the full list of all side effects and restrictions with Sutent, see the package leaflet.

Why has Sutent been approved?

The CHMP decided that Sutent’s benefits are greater than its risks and recommended that it be given marketing authorisation.

Sutent was originally given ‘conditional approval’ because there was more evidence to come about the medicine, in particular in the treatment of renal cell carcinoma. As the company has supplied the additional information necessary, the authorisation has been switched from conditional to full approval.

What measures are being taken to ensure the safe and effective use of Sutent?

A risk management plan has been developed to ensure that Sutent is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Sutent, including the appropriate precautions to be followed by healthcare professionals and patients.

Other information about Sutent

The European Commission granted a conditional marketing authorisation valid throughout the European Union for Sutent on 19 July 2006. This was switched to a full marketing authorisation on 11 January 2007.

For more information about treatment with Sutent, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Name Language First published Last updated
Sutent : EPAR - Summary for the public BG = bălgarski 2009-08-12 2014-10-03
Sutent : EPAR - Summary for the public ES = español 2009-08-12 2014-10-03
Sutent : EPAR - Summary for the public CS = čeština 2009-08-12 2014-10-03
Sutent : EPAR - Summary for the public DA = dansk 2009-08-12 2014-10-03
Sutent : EPAR - Summary for the public DE = Deutsch 2009-08-12 2014-10-03
Sutent : EPAR - Summary for the public ET = eesti keel 2009-08-12 2014-10-03
Sutent : EPAR - Summary for the public EL = elliniká 2009-08-12 2014-10-03
Sutent : EPAR - Summary for the public EN = English 2009-08-12 2014-10-03
Sutent : EPAR - Summary for the public FR = français 2009-08-12 2014-10-03
Sutent : EPAR - Summary for the public IT = italiano 2009-08-12 2014-10-03
Sutent : EPAR - Summary for the public LV = latviešu valoda 2009-08-12 2014-10-03
Sutent : EPAR - Summary for the public LT = lietuvių kalba 2009-08-12 2014-10-03
Sutent : EPAR - Summary for the public HU = magyar 2009-08-12 2014-10-03
Sutent : EPAR - Summary for the public MT = Malti 2009-08-12 2014-10-03
Sutent : EPAR - Summary for the public NL = Nederlands 2009-08-12 2014-10-03
Sutent : EPAR - Summary for the public PL = polski 2009-08-12 2014-10-03
Sutent : EPAR - Summary for the public PT = português 2009-08-12 2014-10-03
Sutent : EPAR - Summary for the public RO = română 2009-08-12 2014-10-03
Sutent : EPAR - Summary for the public SK = slovenčina 2009-08-12 2014-10-03
Sutent : EPAR - Summary for the public SL = slovenščina 2009-08-12 2014-10-03
Sutent : EPAR - Summary for the public FI = suomi 2009-08-12 2014-10-03
Sutent : EPAR - Summary for the public SV = svenska 2009-08-12 2014-10-03
Sutent : EPAR - Summary for the public HR = Hrvatski 2009-08-12 2014-10-03

This EPAR was last updated on 14/11/2016 .

Authorisation details

Product details

Product details for Sutent
NameSutent
Agency product numberEMEA/H/C/000687
Active substance

sunitinib

International non-proprietary name (INN) or common name

sunitinib

Therapeutic area Neuroendocrine TumorsGastrointestinal Stromal TumorsCarcinoma, Renal Cell
Anatomical therapeutic chemical (ATC) code L01XE04

Publication details

Publication details for Sutent
Marketing-authorisation holder

Pfizer Limited

Revision29
Date of issue of marketing authorisation valid throughout the European Union19/07/2006

Contact address:

Pfizer Limited
Ramsgate Road
Sandwich
Kent
CT13 9NJ
United Kingdom

Product information

Product information

09/11/2016  Sutent -EMEA/H/C/000687 -R/0062

Name Language First published Last updated
Sutent : EPAR - Product Information HR = Hrvatski 2009-11-18 2016-11-14
Sutent : EPAR - Product Information HR = Hrvatski 2009-11-18 2016-11-14
Sutent : EPAR - Product Information HR = Hrvatski 2009-11-18 2016-11-14
Sutent : EPAR - Product Information HR = Hrvatski 2009-11-18 2016-11-14
Sutent : EPAR - Product Information HR = Hrvatski 2009-11-18 2016-11-14
Sutent : EPAR - Product Information HR = Hrvatski 2009-11-18 2016-11-14
Sutent : EPAR - Product Information HR = Hrvatski 2009-11-18 2016-11-14
Sutent : EPAR - Product Information HR = Hrvatski 2009-11-18 2016-11-14
Sutent : EPAR - Product Information HR = Hrvatski 2009-11-18 2016-11-14
Sutent : EPAR - Product Information HR = Hrvatski 2009-11-18 2016-11-14
Sutent : EPAR - Product Information HR = Hrvatski 2009-11-18 2016-11-14
Sutent : EPAR - Product Information HR = Hrvatski 2009-11-18 2016-11-14
Sutent : EPAR - Product Information HR = Hrvatski 2009-11-18 2016-11-14
Sutent : EPAR - Product Information HR = Hrvatski 2009-11-18 2016-11-14
Sutent : EPAR - Product Information HR = Hrvatski 2009-11-18 2016-11-14
Sutent : EPAR - Product Information HR = Hrvatski 2009-11-18 2016-11-14
Sutent : EPAR - Product Information HR = Hrvatski 2009-11-18 2016-11-14
Sutent : EPAR - Product Information HR = Hrvatski 2009-11-18 2016-11-14
Sutent : EPAR - Product Information HR = Hrvatski 2009-11-18 2016-11-14
Sutent : EPAR - Product Information HR = Hrvatski 2009-11-18 2016-11-14
Sutent : EPAR - Product Information HR = Hrvatski 2009-11-18 2016-11-14
Sutent : EPAR - Product Information HR = Hrvatski 2009-11-18 2016-11-14
Sutent : EPAR - Product Information HR = Hrvatski 2009-11-18 2016-11-14
Sutent : EPAR - Product Information HR = Hrvatski 2009-11-18 2016-11-14
Sutent : EPAR - Product Information HR = Hrvatski 2009-11-18 2016-11-14

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.


Name Language First published Last updated
Sutent : EPAR - All Authorised presentations HR = Hrvatski 2009-08-12  
Sutent : EPAR - All Authorised presentations HR = Hrvatski 2009-08-12  
Sutent : EPAR - All Authorised presentations HR = Hrvatski 2009-08-12  
Sutent : EPAR - All Authorised presentations HR = Hrvatski 2009-08-12  
Sutent : EPAR - All Authorised presentations HR = Hrvatski 2009-08-12  
Sutent : EPAR - All Authorised presentations HR = Hrvatski 2009-08-12  
Sutent : EPAR - All Authorised presentations HR = Hrvatski 2009-08-12  
Sutent : EPAR - All Authorised presentations HR = Hrvatski 2009-08-12  
Sutent : EPAR - All Authorised presentations HR = Hrvatski 2009-08-12  
Sutent : EPAR - All Authorised presentations HR = Hrvatski 2009-08-12  
Sutent : EPAR - All Authorised presentations HR = Hrvatski 2009-08-12  
Sutent : EPAR - All Authorised presentations HR = Hrvatski 2009-08-12  
Sutent : EPAR - All Authorised presentations HR = Hrvatski 2009-08-12  
Sutent : EPAR - All Authorised presentations HR = Hrvatski 2009-08-12  
Sutent : EPAR - All Authorised presentations HR = Hrvatski 2009-08-12  
Sutent : EPAR - All Authorised presentations HR = Hrvatski 2009-08-12  
Sutent : EPAR - All Authorised presentations HR = Hrvatski 2009-08-12  
Sutent : EPAR - All Authorised presentations HR = Hrvatski 2009-08-12  
Sutent : EPAR - All Authorised presentations HR = Hrvatski 2009-08-12  
Sutent : EPAR - All Authorised presentations HR = Hrvatski 2009-08-12  
Sutent : EPAR - All Authorised presentations HR = Hrvatski 2009-08-12  
Sutent : EPAR - All Authorised presentations HR = Hrvatski 2009-08-12  

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Gastrointestinal stromal tumour (GIST)

Sutent is indicated for the treatment of unresectable and / or metastatic malignant GIST after failure of imatinib-mesilate treatment due to resistance or intolerance.

Metastatic renal-cell carcinoma (MRCC)

Sutent is indicated for the treatment of advanced / MRCC in adults.

Pancreatic neuroendocrine tumours (pNET)

Sutent is indicated for the treatment of unresectable or metastatic, well differentiated pNET with disease progression in adults.

Experience with Sutent as first-line treatment is limited.

Assessment History

Changes since initial authorisation of medicine

Initial marketing-authorisation documents

Name Language First published Last updated
Sutent : EPAR - Scientific Discussion HR = Hrvatski 2007-01-10  
Sutent : EPAR - Procedural steps taken before authorisation HR = Hrvatski 2006-08-01  

Authorised

This medicine is approved for use in the European Union

More information on Sutent

This product is no longer an orphan medicine. It was originally designated an orphan medicine for the following orphan indications:

Sutent was withdrawn from the Community register of orphan medicinal products in July 2008 upon request of the marketing authorisation holder.